Hepatitis C NS5B polymerase inhibitors: 4,4-Dialkyl-1-hydroxy-3-oxo-3,4-dihydronaphthalene-3-yl benzothiadiazine derivatives
摘要:
4,4-Dialkyl-1-hydroxy-3-oxo-3.4-dihydronaphthalene-3-yl benzothiadiazine derivatives were synthesized and evaluated as inhibitors of genotypes 1a and 1b HCV NS5B polymerase. A number of these compounds exhibited potent activity against genotypes 1a and 1b HCV polymerase in both enzymatic and cell culture activities. A representative compound also showed favorable pharmacokinetics in the rat. (C) 2008 Elsevier Ltd. All rights reserved.
DOI:
10.1016/j.bmcl.2008.06.043
作为产物:
描述:
3-[7-(benzyloxy)-1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl]-4-hydroxy-1,1-dipropyl-2(1H)-naphthalenone 在
钯氢气 作用下,
以
tetrahydrofuran-ethyl acetate methanol 为溶剂,
反应 18.0h,
以to afford the title compound (86 mg, 94%)的产率得到4-hydroxy-3-(7-hydroxy-1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-1,1-dipropyl-2(1H)-naphthalenone
Compounds having the formula
are hepatitis C(HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C(HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.
[EN] 1, 1-DIOXIDO-4H-1,2,4-BENZOTHIADIAZINE DERIVATE UND VERWANDTE VERBINDUNGEN ALS INHIBITOREN DER HCV POLYMERASE ZUR BEHANDLUNG VON HEPATITIS C<br/>[FR] AGENTS ANTI-INFECTIEUX
Compounds having the formula (I), wherein B is (a), (b), (c), or (d); A is a monocyclic or bicyclic ring selected from the group consisting of aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocycle (the other substituents are defined in the claims), are hepatitis C (HCV) polymerase inhibitors. Also disclosed are a composition processes for making the compounds, and synthetic intermediates employed in the processes.